Jardiance Dosage

Generic name: EMPAGLIFLOZIN 10mg
Dosage form: tablet, film coated
Drug class: SGLT-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Nov 21, 2023.

Testing Prior to Initiation of JARDIANCE

Assess renal function before initiating JARDIANCE and as clinically indicated [see Warnings and Precautions (5.2)].
- Use for glycemic control is not recommended in patients with an eGFR less than 30 mL/min/1.73 m2 [see Use in Specific Populations (8.6)].
Assess volume status. In patients with volume depletion, correct this condition before initiating JARDIANCE [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].

Recommended Dosage

Table 1 presents the recommended dosage of JARDIANCE in adult and pediatric patients aged 10 years and older.

Table 1 Recommended Dosage of JARDIANCE
Population	Indication	Recommended Dosage
Adults	Reduce the risk of cardiovascular death and hospitalization in patients with heart failure	10 mg orally once daily in the morning, taken with or without food.
	Reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
	Reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus with established cardiovascular disease
	Glycemic control in type 2 diabetes mellitus	10 mg orally once daily in the morning, taken with or without food. For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily.
Pediatric patients aged 10 years and older	Glycemic control in type 2 diabetes mellitus	10 mg orally once daily in the morning, taken with or without food. For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily.

Recommendations Regarding Missed Dose

If a dose is missed, instruct patients to take the dose as soon as possible.
Do not double up the next dose.

Temporary Interruption for Surgery

Withhold JARDIANCE for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting. Resume JARDIANCE when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].